Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma, Inc. - Common Stock (NQ: SILO )

1.420 -0.090 (-5.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silo Pharma, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the... 
Via Benzinga
Nasdaq Falls 100 Points; Dermata Therapeutics Shares Surge
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 100 points on Friday. 
Via Benzinga
Silo Pharma (NASDAQ: SILO) Reports Positive Results from Dose Optimization Study for SPU-21 and Treatment of Arthritis
Silo Pharma, Inc. (NASDAQ: SILO) operates as a development-stage biopharmaceutical company, which is focused on combining traditional therapies with psychedelics 
Via Spotlight Growth
Silo Pharma Stock Surges After Positive Study Results From Arthritis Study
Via Benzinga
US Stocks Open Lower; Dow Drops 250 Points
U.S. stocks traded lower this morning, with the Dow Jones dropping around 250 points on Friday. 
Via Benzinga
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END 
Via FinancialNewsMedia
Silo Pharma Announces Positive Study Results of SPU
21 for Arthritis – SPU-21 effective in controlling arthritis progression SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide Englewood Cliffs, – December... 
Via FinancialNewsMedia
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) CEO Discusses Advancement of Pipeline, Positioning in Shareholder Letter
Via Investor Brand Network
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue
Via Investor Brand Network
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
From Silo Pharma, Inc.
Via GlobeNewswire
7 Millionaire-Maker Stocks You Will Regret Not Buying This Year
With the market shifting toward a deflationary stance, investors should target these robust millionaire-maker stocks to buy. 
Via InvestorPlace
Novel Psychedelic Compound For The Treatment Of Fibromyalgia Begins Dosing In Safety Trial
Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begu 
Via Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation
Via Investor Brand Network
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
From Silo Pharma, Inc.
Via GlobeNewswire
New Psychedelic Journal to Focus on Publishing Psychedelic Research
Via Investor Brand Network
Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation
Via Investor Brand Network
Microscopy Provides Insights on Psychedelics Action Inside Neuropathways
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Present at Largest Gathering in Psychedelic Medicine Sector
Via Investor Brand Network
Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions
Via Investor Brand Network
What You Should Know About Colorado’s Psychedelics Ballot Measure
Via Investor Brand Network
Silo Pharma Inc.’s (NASDAQ: SILO) Novel Ketamine Formulation Undergoing Safety Evaluation, Pursuing Regulatory Pathway
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Data Supporting SPC-14’s Therapeutic Potential for Alzheimer’s
Via Investor Brand Network
Exposures Product Safety
What Is Going on With Silo Pharma (SILO) Stock Today?
Silo Pharma (SILO) stock is falling on Thursday despite the company releasing positive data from a pre-clinical Alzheimer's study. 
Via InvestorPlace
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which... 
Via FinancialNewsMedia
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
Dosing study of SPC-14 demonstrates efficacy for increasing memory function Englewood Cliffs, NJ – October 20, 2022 – Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage... 
Via FinancialNewsMedia
Silo Pharma Posts Encouraging Preclinical Data For Alzheimer's Candidate
Silo Pharma Inc (NASDAQ: SILO) has announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD). The research was conducted as part of a... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.